EVO ICL Indications
The EVO Implantable Collamer Lens is indicated for adult patients aged 21-45 years who desire reduced dependence on eyeglasses or contact lenses and have myopia ranging from -3.00 D to -20.00 D with astigmatism up to 4.00 D, provided they have stable refraction and adequate anterior chamber depth. 1, 2
Primary Indication
Refractive correction for patients seeking spectacle independence who meet specific criteria for phakic intraocular lens implantation. 1
Specific Refractive Parameters (FDA-Approved)
- Myopia range: -3.00 D to -20.00 D spherical equivalent 2
- Astigmatism: Up to 4.00 D 2
- Age requirement: 21 through 45 years 3, 2
- Refraction stability: Must demonstrate stable refraction (unstable refraction is an absolute contraindication) 1
The FDA approval in March 2022 was based on a multicenter trial of 629 eyes demonstrating 90.5% of eyes within ±0.50 D of target at 6 months, with efficacy and safety indices of 1.06 and 1.24 respectively. 2
Patient Selection Criteria
Must Have:
- Desire to reduce dependence on corrective lenses for occupational, cosmetic, or lifestyle reasons 1
- Adequate anterior chamber depth (shallow anterior chamber is a contraindication) 1
- Healthy corneal endothelium without Fuchs dystrophy or other endothelial disease 1
- Controlled ocular surface without significant blepharitis, dry eye, or atopy 1
Absolute Contraindications to Avoid:
- Visually significant cataract 1
- Active or recurrent uveitis requiring ongoing treatment 1
- Uncontrolled glaucoma 1
- Corneal endothelial disease including Fuchs dystrophy 1
- Uncontrolled mental illness including anxiety or depression 1
- Unrealistic patient expectations 1
Relative Contraindications Requiring Careful Assessment:
- Functional monocularity 1
- Pseudoexfoliation 1
- History of uveitis (even if currently inactive) 1
- Diabetes mellitus 1
- Pregnancy or lactation 1
- Autoimmune or immune-mediated disease 1
Clinical Advantages of EVO Design
The central port (KS Aquaport) design eliminates the need for preoperative peripheral iridotomy, a significant advancement over earlier ICL models. 3, 2, 4 This design allows physiologic aqueous humor flow, reducing complications:
- Zero cases of pupillary block in the FDA trial of 629 eyes 2
- No peripheral iridotomy/iridectomy required preoperatively or postoperatively 3, 2
- Reduced anterior subcapsular cataract rate: Only 0.16% at 2 years (1 eye out of 629) compared to 1.0-2.3% with earlier models 3, 4
- No elevated IOP from angle narrowing or pigment dispersion 2
Expected Outcomes
Refractive Accuracy:
- 90.7% within ±0.50 D of target at 3 years 3
- 99.0% within ±1.00 D of target at 3 years 3
- Mean spherical equivalent: -0.12 ± 0.30 D at 3 years (from preoperative mean of -7.62 ± 2.75 D) 3
Visual Acuity:
- 48.9% of eyes gained ≥1 line of CDVA at 3 years 3
- Mean postoperative UDVA: -0.053 ± 0.12 logMAR 3
- Safety index: 1.25 at 3 years 3
Safety Profile:
- Mean endothelial cell loss: 6.7% at 3 years, approaching stability 3
- Lens exchange rate: 0.32% (2 eyes out of 629) for high vault 3
- Cataract formation: 0.16% anterior subcapsular cataract at 2 years 3
Critical Pitfalls to Avoid
Surgeon experience directly correlates with complication rates, particularly cataract formation with posterior chamber phakic IOLs. 1, 5 Inadequate pupil dilation during implantation increases risk of haptic adhesion and incomplete unfolding. 5
Vault assessment is critical: Abnormal vault is associated with 1-2.3% cataract formation risk and accounts for approximately 7% of ICL explantations due to lens dislocation or decentration. 5 Forceful manipulation during positioning can cause endothelial cell loss or iris trauma. 5
Preoperative cycloplegic refraction is essential in younger patients to ensure accurate refractive measurements, as accommodation can mask true refractive error. 1